logo
Twitter
Discord
Email
logo
logo
Cartesian Therapeutics, Inc.NASDAQ - RNAC
Reports
Search reports
Name
Reporting Date
Filing Date
2024-09-30 10-Q2024-09-302024-11-07
2024-06-30 10-Q2024-06-302024-08-08
2024-03-31 10-Q2024-03-312024-05-08
2023-12-31 10-K2023-12-312024-03-07
2023-09-30 10-Q2023-09-302023-11-13
2023-06-30 10-Q2023-06-302023-08-17
2023-03-31 10-Q2023-03-312023-05-04
2022-12-31 10-K2022-12-312023-03-02
2022-09-30 10-Q2022-09-302022-11-03
2022-06-30 10-Q2022-06-302022-08-08
2022-03-31 10-Q2022-03-312022-05-05
2021-12-31 10-K2021-12-312022-04-28
2021-12-31 10-K2021-12-312022-03-10
2021-09-30 10-Q2021-09-302021-11-09
2021-06-30 10-Q2021-06-302021-08-12
2021-03-31 10-Q2021-03-312021-05-13
2020-12-31 10-K2020-12-312021-03-12
2020-09-30 10-Q2020-09-302020-11-05
2020-06-30 10-Q2020-06-302020-08-06
2020-03-31 10-Q2020-03-312020-05-07
1
2
20 / page
About
Name
Cartesian Therapeutics, Inc.
Overview
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.
Show More
CEO
Dr. Carsten Brunn Ph.D.
Industry
Biotechnology
Exchange
NASDAQ
Listing Date
2016-06-22
Address
704 Quince Orchard Road, Gaithersburg, MD, 20878, United States
Tel
617-923-1400
Website
https://www.cartesiantherapeutics.com